Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPCByHannah ClarkeNovember 6th 2023The median overall survival with niraparib, abiraterone acetate, and prednisone was 30.4 months vs 28.6 months with abiraterone acetate and prednisone alone.